ClinicaliQ Trial Snapshot
- Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — Recruiting • Phase III • NCT06679881.
- Long-term study showing a daily tablet (deucrictibant) safely prevents angioedema attacks in teenagers and adults with hereditary angioedema.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema Conditions: Hereditary Angioedema (HAE) Interventions: Deucrictibant Lead Sponsor: Pharvaris Netherlands B.V. Planned Enrollment: 170 participants